Lexaria Bioscience (LEXX) Intangibles (2015 - 2026)
Lexaria Bioscience (LEXX) posted Intangibles of $339016.0 for Q2 2026, up 6.59% sequentially from $318058.0 in Q1 2026, and up 460.39% YoY from $60496.0 in Q2 2025.
Lexaria Bioscience (LEXX) Intangibles (2015 - 2026) Analysis & Trends
Lexaria Bioscience has reported Intangibles for 12 years, with the latest figure at $339016.0 in Q2 2026.
- Quarterly Intangibles rose 460.39% year-over-year to $339016.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $339016.0 (up 460.39% YoY) and the FY2025 annual result came in at $307818.0, down 40.42% from the prior year.
- Intangibles advanced to $339016.0 in Q2 2026 per LEXX's latest filing, from $318058.0 in the prior quarter.
- Over five years, Intangibles peaked at $519253.0 in Q1 2024 and troughed at $40026.0 in Q4 2023.
- A 5-year average of $332357.5 and a median of $389845.5 in 2022 frame the typical range for Intangibles.
- The sharpest annual moves came in 2024 and 2025: Intangibles soared 1162.61% in 2024, then tumbled 92.09% in 2025.
- Over 5 years, Intangibles stood at $500549.0 in 2022, then sank by 92.0% to $40026.0 in 2023, then jumped by 1162.61% to $505373.0 in 2024, then sank by 39.04% to $308060.0 in 2025, then increased by 10.05% to $339016.0 in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $339016.0, $318058.0, and $308060.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 46,445.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 339,016.00 |
| Feb 28, 2026 | 318,058.00 |
| Nov 30, 2025 | 308,060.00 |
| Aug 31, 2025 | 307,818.00 |
| May 31, 2025 | 60,496.00 |
| Feb 28, 2025 | 41,052.00 |
| Nov 30, 2024 | 505,373.00 |
| Aug 31, 2024 | 516,676.00 |
| May 31, 2024 | 498,878.00 |
| Feb 29, 2024 | 519,253.00 |
| Nov 30, 2023 | 40,026.00 |
| Aug 31, 2023 | 462,625.00 |
| May 31, 2023 | 67,425.00 |
| Feb 28, 2023 | 517,730.00 |
| Nov 30, 2022 | 500,549.00 |
| Aug 31, 2022 | 488,462.00 |
| May 31, 2022 | 440,675.00 |
| Feb 28, 2022 | 50,263.00 |
| Nov 30, 2021 | 378,746.00 |
| Aug 31, 2021 | 364,623.00 |